Amgen Inc. (AMGN) — Fair Value Analysis

Base-case fair value (P50): $294.13 · Current price: $326.31 · Verdict: Fairly Valued

The Verdict on AMGN

Our Monte Carlo simulations indicate Amgen (AMGN), a key player in the Healthcare sector, is Fairly Valued at its current price of $326.31. While the stock presently trades above our median fair value (P50) of $294.13, this -9.9% gap suggests a valuation that aligns reasonably with its intrinsic worth based on thousands of simulated future scenarios. Investors should note this nuanced position rather than viewing the current price as a clear overvaluation.

How AMGN stacks up against Healthcare

Amgen's operational and financial health is currently assessed as "average" relative to its Healthcare sector peers. This quality tier means that while AMGN demonstrates solid fundamentals, it doesn't present an exceptional margin of safety or growth premium compared to other companies in the sector, especially when considering its current price of $326.31. The Fairly Valued verdict, therefore, reflects a balanced assessment, accounting for both its quality tier and the -9.9% difference from our $294.13 estimate.

What this means for investors

For investors tracking AMGN, the Fairly Valued assessment suggests that the stock is neither a screaming buy nor a clear short opportunity at $326.31. The Monte Carlo simulation, which generates a $294.13 median fair value, provides a probabilistic framework for understanding Amgen's valuation. While some downside scenarios exist, the overall distribution suggests that the current market price is a reasonable reflection of its intrinsic value. To fully understand potential upside or downside scenarios, including the complete probabilistic distribution, sign up for a free FairCurve account. This allows you to track AMGN's fair value as new fundamentals are released and see the full bear/bull distribution.